AC
PCVX icon

Allstate Corporation’s Vaxcyte PCVX Stock Holding History

Allstate Corporation’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$835K Sell
14,370
-4,424
-24% -$240K 0.01% 825
2026
Q1 		$1.09M Buy
+18,794
New +$1.02M 0.01% 778

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Allstate Corporation's PCVX Position: Q2 2026 in Review

Allstate Corporation reduced its Vaxcyte (PCVX) stake by 24% in Q2 2026, selling an estimated $240K and leaving 14,370 shares worth $835K. The position accounts for 0.01% of the portfolio, ranked #825.

Allstate Corporation first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.09M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Allstate Corporation held 14,370 shares of Vaxcyte worth $835K as of Q2 2026.
  • Allstate Corporation sold 4,424 Vaxcyte shares in Q2 2026, an estimated $240K.
  • Vaxcyte made up 0.01% of Allstate Corporation's portfolio in Q2 2026, its #825 holding.
  • Allstate Corporation first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
  • Allstate Corporation's Vaxcyte position peaked at $1.09M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.